Speaker: Andrew Brunner

1:05:39

Post ASCO/EHA 2023 Roundtable Discussion on the latest updates in MDS

1:26:15

Updates on MDS Classifications

0:01:41

The role of antibody-based therapies in MDS treatment

0:23:22

iwMDS wrap-up: translating research into practice to optimize patient care

0:01:54

Real-world effectiveness of midostaurin versus quizartinib in FLT3-ITD mutated AML

0:01:37

Are we ready for triplet therapy in MDS?

0:01:27

The impact of inflammation & the microenvironment in the development and progression of MDS

0:02:20

Investigating the economic burden associated with treating older patients with newly diagnosed AML

0:05:17

Advances in the treatment of LR-MDS: luspatercept combinations, the use of imetelstat & more

0:01:41

An overview of the MDS diagnosis pathway

0:03:08

The treatment protocol for higher risk MDS

0:03:32

Evaluating response criteria in myelodysplastic syndromes

0:03:38

Evaluating therapies in MDS

0:02:12

Improving the treatment of low-risk MDS: luspatercept, treatment sequencing & disease classification

0:03:03

The oral ATR inhibitor ceralasertib in patients with MDS or CMML

0:02:41

The addition of lenalidomide to MEC chemotherapy to improve outcomes of patients with R/R AML

0:02:13

Optimizing therapy for patients with high-risk MDS

0:02:40

Safety and efficacy of sabatolimab plus azacitidine or decitabine in patients with HR-MDS and AML

0:01:14

Novel therapies on the horizon for MDS

0:01:19

Future directions in MDS

0:00:52

Benefits of a virtual EHA 2021 meeting

0:02:18

Antibody therapies for AML and MDS

1:31:23

MDS CLASSIFICATION & PROGNOSIS

0:09:25

Improving MDS management: new targets, drug combinations, and personalized and cellular therapies